We a novel first in-class treatment for Endometriosis based on the immune system.
FimmCyte has raised €1.2M across 2 funding rounds from 2 investors, most recently a Debt round in Feb 2024. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-02-29 | Debt | €1.0M | UZH Life Sciences Fund (LSF) | View deal → |
| 2022-07-13 | Other | €153k | Venture Kick | View deal → |
